Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy

Liver International

Volumn 36, Issue 5, 2016, Pages 688-695

  Finkenstedt, Armin ^a   Vikoler, Anja ^a   Portenkirchner, Manuela ^a   Mülleder, Kerstin ^a   Maglione, Manuel ^a   Margreiter, Christian ^a   Moser, Patrizia ^b   Vogel, Wolfgang ^a   Bale, Reto ^a   Freund, Martin ^a   Luger, Anna ^a   Tilg, Herbert ^a   Petersen, Johannes ^a   Schneeberger, Stefan ^a   Graziadei, Ivo ^c   Zoller, Heinz ^a   Glodny, Bernhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatoma; Liver transplantation; Milan criteria

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; AUSTRIA; CANCER GRADING; DISEASE EXACERBATION; EPIDEMIOLOGY; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AUSTRIA; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; GRAFT SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84963984721     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12966     Document Type: Article

References (26)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
2. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
4. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873-83.
5. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
6. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
7. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-74.
8. Kaido T, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 538-40.
9. Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011; 55: 1137-47.
10. Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19: 7515-30.
11. Lei J, Wang W, Yan L. Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria. J Gastrointest Surg 2013; 17: 1440-6.
12. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-7.
13. Ravaioli M, Grazi GL, Piscaglia F, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547-57.
14. Cucchetti A, Cescon M, Bigonzi E, et al. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-54.
15. Vitale A, D'Amico F, Frigo AC, et al. Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17: 2290-302.
16. Freeman RB Jr, Steffick DE, Guidinger MK, et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008; 8: 958-76.
17. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-75.
18. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-9.
19. Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-18.
20. Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013; 11: 1667-72.
21. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
22. Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 2010; 30: 052-60.
23. D'Amico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15: 1278-87.
24. De Luna W, Sze DY, Ahmed A, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009; 9: 1158-68.
25. Lai Q, Avolio AW, Lerut J, et al. Recurrence of hepatocellular cancer after liver transplantation: the role of primary resection and salvage transplantation in East and West. J Hepatol 2012; 57: 974-9.
26. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 1086-92.